189 results about "Response to treatment" patented technology

Treatment of hypertension includes implantation of the discharge portion(s) of a catheter and / or electrical stimulation electrode(s) adjacent the tissue(s) to be stimulated. Stimulation pulses, i.e., drug infusion pulses and / or electrical pulses, are supplied by one or more implanted stimulators, through the catheter and possibly also a lead, tunneled subcutaneously between the stimulator and stimulation site. A microstimulator(s) may also / instead deliver electrical stimulation pulses. Stimulation sites include the carotid sinus and carotid body, among other locations. Treatments include drugs used for acute and / or chronic treatment of hypertension. In a number of embodiments, a need for or response to treatment is sensed, and the electrical and / or infusion pulses adjusted accordingly.

A system and method of obtaining serial biochemical, anatomical or physiological in vivo measurements of disease from one or more medical images of a patient before, during and after treatment, and measuring extent and severity of the disease is provided. First anatomical and functional image data sets are acquired, and form a first co-registered composite image data set. At least a volume of interest (ROI) within the first co-registered composite image data set is identified. The first co-registered composite image data set including the ROI is qualitatively and quantitatively analyzed to determine extent and severity of the disease. Second anatomical and functional image data sets are acquired, and form a second co-registered composite image data set. A global, rigid registration is performed on the first and second anatomical image data sets, such that the first and second functional image data sets are also globally registered. At least a ROI within the globally registered image data set using the identified ROI within the first co-registered composite image data set is identified. A local, non-rigid registration is performed on the ROI within the first co-registered composite image data set and the ROI within the globally registered image data set, thereby producing a first co-registered serial image data set. The first co-registered serial image data set including the ROIs is qualitatively and quantitatively analyzed to determine severity of the disease and / or response to treatment of the patient.

Disclosed is a system and method of assessing the efficacy of and predicting response to treatment of neurological or psychological disorders. The preferred embodiment uses at least two surface electrodes to acquire EEG signals from the surface of a patient's body, a processor for computing from the EEG signals various features and indices that are representative of the patient's neurological or psychological state. Pretreatment indices represent a patient's neurological or psychological state and therefore may be used to predict the response to treatment. Changes in these parameters may be used to assess the efficacy of treatment and to modify the treatment to optimize the resultant patient state.

The present invention provides apparatuses and methods for creating a physiologic database or library that can be indexed to at least health, disease, patient characteristics, and acute medical crises or other dangerous condition. The present invention also provides apparatuses and methods for creating an athletic performance database or library. The database can be structured and continuous / pseudo-continuous modeling statistics applied to provide novel insight into performance and progress of an athlete or group of athletes, as well as standing relative to other athletes, or to provide novel insight into the natural history of disease and the response to treatment, and ultimately to improve care delivery.

The present invention provides protein-based biomarkers and biomarker combinations that are useful in qualifying Alzheimer's disease status in a patient. In particular, the biomarkers of this invention are useful to classify a subject sample as Alzheimer's or non-Alzheimer's dementia or normal. The biomarkers can be detected by SELDI mass spectrometry. In addition, the invention provides appropriate treatment interventions and methods for measuring response to treatment. Certain biomarkers of the invention may also be suitable for employment as radio-labeled ligands in non-invasive imaging techniques such as Positron Emission Tomography (PET).

This invention involves use of temporal or spatio / spector-temporal data (SSTD) for early classification of outputs that are results of spatio-temporal patterns of data. Classification models are based on spiking neural networks (SNN) suitable to learn and classify SSTD. The invention may predict early events in many applications, i.e. engineering, bioinformatics, neuroinformatics, predicting response to treatment of neurological and brain disease, ecology, environment, medicine, and economics, among others. The invention involves a method and system for personalized modelling of SSTD and early prediction of events based on evolving spiking neural network reservoir architecture (eSNNr). The system includes a spike-time encoding module to encode continuous value input information into spike trains, a recurrent 3D SNNr and an eSSN as an output classification module.

A method and technique to measure vaginal skin biomechanical properties in vivo by applying a temporary deforming force to the vaginal skin while using sensors to monitor and record the vaginal skins response to the deforming force as well as how it responds after the deforming force is removed. By placing a female participant in the correct anatomical position and employing a vaginal biomechanical evaluation tool to temporarily distort and measure the vaginal skin an examiner is able to obtain measurements for biomechanical properties of the vaginal skin. These measurements may allow clinicians and medical researchers to understand a woman's vaginal tissue quality, response to treatment, and risk for future pelvic floor disorders more completely in order to take appropriate prophylactic or corrective action.

We analyzed bone marrow from 67 patients from a phase 2 study of farnesyltransferase inhibition with tipifarnib (R115777, ZARNESTRA®), in older adults with previously untreated, poor-risk acute myeloid leukemia (AML) for N-Ras mutations, global gene expression, and / or quantitative PCR (qPCR) of specific genes. Microarray profiling identified a two-gene expression ratio (RASGRP1:APTX) which provided the greatest accuracy for predicting response to tipifarnib. We demonstrated that this classifier could predict response to tipifarnib in an independent set of 54 samples from relapsed or refractory AML, with a NPV and PPV of 92% and 28%, respectively (odds ratio of 4.4). Therefore, in both newly diagnosed and relapsed or refractory AML, this classifier improves the overall response rate by approximately 50% while maintaining a high NPV, and significantly improves patient overall survival. The two-gene classifier was also validated by qPCR in thirty AML samples from the same clinical study demonstrating a negative predictive value (NPV) and positive predictive value (PPV) of 81% and 50%, respectively (odds ratio of 4.3). These data indicate that a simple two-gene expression assay may have utility in diagnosing a population of AML patients who are more likely to respond to tipifarnib.

The present inventions relates to methods and assays to predict the response of an individual to a psychiatric treatment and to a method to improve medical treatment of a disorder, which is responsive to treatment with a psychiatric treatment.

Methods of treating or managing specific cancers, including non-Hodgkin's lymphoma, by the administration of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Methods of using gene and protein biomarkers as a predictor of non-Hodgkin's lymphoma response to treatment with 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione are also disclosed.

A cancer test having prognostic utility in predicting time to disease progression, overall survival, and response to therapy in patients with MBC based upon the presence and number of CTC's. The Cell Spotter® System is used to enumerate CTC's in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies CTC's. The absolute number of CTC's detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. The mean time to survival of patients depended upon a threshold number of 5 CTC's per 7.5 ml of blood. Detection of CTC's in metastatic cancer represents a novel prognostic factor in patients with metastatic cancers, suggests a biological role for the presence of tumor cells in the blood, and indicates that the detection of CTC's could be considered an appropriate surrogate marker for prospective therapeutic clinical trials.

The present invention provides single nucleotide polymorphisms (SNPs) associated with clinical responsiveness of rheumatoid arthritis patients to treatment with an interleukin-6 receptor antibody such as tocilizumab, and methods of using such SNPs for predicting clinical response to treatment with the antibody.

This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and / or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.

The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus and drug-induced lupus erythematosus by measuring cell-based complement activation products in a subject's blood. In particular, the invention describes a diagnostic method employing the measurement of multiple complement activation products, such as C3d and C4d, on the surfaces of red blood cells, white blood cells, and platelets. Kits and automated systems for performing the methods of the invention are also disclosed.

The invention provides methods, nucleic acids, compositions and kits for predicting a subject's response to treatment with one or more vasopressin receptor agonists to identify subjects having a greater benefit from treatment with vasopressin receptor agonist(s). The method generally comprises determining a vasopressin pathway associated gene polymorphism genotype(s) of a subject for one or more polymorphisms in the these genes, comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response genotype to identify potential subjects having an inflammatory condition who are more likely to benefit from treatment with a vasopressin receptor agonist and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with vasopressin receptor agonists based on the subject's genotype.

The present invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial response to treatment response with chemotherapy.

A method for prognostic or diagnostic assessment of a gastrointestinal-related disorder, such as ulcerative colitis, in a subject correlates the presence, absence, and / or magnitude of a gene in a sample with a reference standard to determine the presence and / or severity of the disorder, and / or the response to treatment for the disorder. The method enables identification of the effectiveness of candidate therapies.

A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the α subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.

Methods of utilizing biomarkers to identify patients for treatment or to monitor response to treatment are taught herein. Alterations in levels of gene expression of the biomarkers, particularly in response to Raf kinase inhibition, are measured and identifications or adjustments may be made accordingly.

A system for identifying, monitoring and matching patients with appropriate treatments using a systemic mediator-associated physiologic test profile are provided. The system of the present invention increases the likelihood of demonstrating clinical efficacy in clinical trial datasets.

The present disclosure involves the use of metal-containing texaphyrins and zinc (II) reagents for the treatment of tumors, atheromas and other neoplastic tissue. The present application demonstrates increased oxidative stress, alterations in zinc homeostasis, cell cycle arrest, and apoptosis of cancer cells in the presence of texaphyrins and / or zinc. One aspect is to monitor oxidative stress and / or alterations in zinc homeostasis in target cells prior to and / or after treatment with metal-containing texaphyrins and / or zinc (II) reagents as a predictor for treatment efficacy. The present disclosure provides molecular basis for the cell cycle arrest and apoptosis on cancer cells in the presence of texaphyrins and zinc. Another aspect is to monitor different genes involved in response to treatment with texaphyrins and zinc prior to and / or after treatment as predictors for treatment efficacy.

Described herein are materials and methods for predicting and monitoring a heart failure patient's physiological response to treatment with a statin. More specifically, the present invention relates to the endogenous protein galectin-3 and its use as a predictor of response to treatment with 3-hydroxy-3-methylglutaryl coenzyme-A reductase inhibitors, or statins.

The invention provides, in certain embodiments, a method of preventing and / or treating peritoneal injury and / or diminished function by administering an effective amount of one or more inhibitors of JAK. The invention also provides a pharmaceutical composition including a JAK inhibitor for the treatment of peritoneal injury and / or diminished function. In another aspect, the invention provides a method of detecting an indicator of peritoneal injury. The method entails assaying a biological sample for periostin, wherein the presence of periostin at an elevated level indicates the presence and / or degree of peritoneal injury. Also provided, are methods of identifying subject for treatment of peritoneal injury and / or diminished function, methods of determining progression of these conditions, as well as methods of determining subjects' response to treatment.